Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
Status:
Completed
Trial end date:
2020-09-02
Target enrollment:
Participant gender:
Summary
The treatment of the patients with recurrent and metastatic breast cancer remains a major
problem. There is still a lack of effective targeted therapy for Her-2 negative breast
cancer.Based on the present researches on the anti-angiogenesis drugs in advanced breast
cancer, the investigators believe that it is necessary to further explore the efficacy and
safety of apatinib in advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Cancer Hospital
Collaborators:
Hebei Medical University Fourth Hospital Peking University First Hospital Peking University Third Hospital Shanxi Province Cancer Hospital